EQRx, Inc.

EQRx, Inc. is a pharmaceutical firm dedicated to developing novel therapeutic agents. Its primary focus lies in creating treatments for oncological and immune-inflammatory disorders, with its operations primarily situated in the United States. The company's pipeline includes several key investigational drugs: Aumolertinib, an EGFR inhibitor designed for non-small cell lung cancer (NSCLC) patients with EGFR mutations; Sugemalimab, an anti-PD-L1 antibody targeting advanced (stage III and IV) NSCLC; Lerociclib, a CDK4/6 inhibitor for the treatment of HR+/HER2- breast cancer; and EQ176, an anti-PD-1 antibody currently under evaluation for liver cancer. EQRx has formed strategic alliances with companies like Exscientia and AbCellera Biologics Inc. The company was founded in 2020 and its corporate base is located in Cambridge, Massachusetts.